
|Articles|March 1, 2002
Unoprostone lowers IOP in advanced glaucoma cases
Washington, DC-Unoprostone isopropyl 0.15% (Rescula, Novartis) may be a viable option for further lowering IOP in patients with advanced glaucoma whose disease is uncontrolled by maximum tolerated medical therapy, said Leslie S. Jones, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
2
iOpeners with Nicole Bajic, MD: Mary Qiu, MD, on tailored NVG pathways
3
Long-lived Greenland sharks may point to new approaches for retinal disease
4
Orbital and retinal microvascular changes in thyroid eye disease
5












































